Pascal Meier

Has grant

Principle Investigator

Institute of Cancer Research
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Harnessing cell death mechanisms to overcome treatment resistance and improve tumour immunity

Open Date: 2018-02-01

Close Date: 2023-01-01

Grant: Close

Harnessing TNF-mediated cell death in cancer

Open Date: 2015-06-30

Close Date: 2018-06-29

Grant: Close

Ubiquitin networks in cell death regulation and non-apoptotic signalling

Open Date: 2014-11-03

Close Date: 2018-05-07

Grant: Close

TNF-receptor trafficking and the regulation of inflammation, cell death and cancer

Open Date: 2014-07-01

Close Date: 2017-06-30

Grant: Close

Cell Death Activation to Prevent Late Relapse in Breast Cancer

Open Date: 2012-10-09

Close Date: 2018-04-08

Articles (6)

Immune checkpoint blockade (ICB) has transformed cancer therapy across multiple tumour types, yet primary and acquired resistance remain major barriers to durable benefit. TANK-binding kinase 1 (TBK1) has emerged as an attractive target to enhance anti-tumour immunity, acting as a serine/threonine kinase that restrains immunogenic cell death and downstream immune activation. Here we report the discovery of a first-in-class TBK1 molecular glue degrader (MGD), CCT412020, identified through high-throughput proteomics screening of a next-generation molecular glue library. CCT412020 induces rapid, potent and selective TBK1 degradation across a panel of breast cancer cell lines. A cryo-EM structure of CCT412020 in complex with CRBN/ΔBPB-DDB1 and TBK1-homodimer reveals an unexpected binding mode that bypasses the canonical G-loop and instead engages an unconventional site at the TBK1 homodimer interface. Functionally, TBK1 loss via CCT412020 sensitises tumour cells to TNF- and interferon-driven responses and reduced viability across a broad range of cancer cell lines. Together, these findings establish CCT412020 as a mechanistically distinct TBK1 degrader and provide a framework for developing TBK1-targeted degraders as immunomodulatory anti-cancer agents to overcome ICB resistance.

Year:

2026

Harnessing radiotherapy (RT) to effectively eliminate cancer cells has been a cornerstone of clinical oncology for decades. Beyond its well-established cytotoxic effects, RT triggers a diverse array of tumor cell death modalities, including apoptosis, necrosis, mitotic catastrophe, and, under specific conditions, immunogenic forms such as necroptosis and pyroptosis. Although apoptosis serves as a homeostatic and immunologically silent process that removes over 200 billion cells daily in our body, lytic forms of regulated cell death, such as necroptosis and pyroptosis, have evolved to detect and combat pathogens, thereby acting as potent danger signals that alert and mobilise immune responses. Here, we review emerging pathogen-mimicry approaches to rewire RT-induced cell death towards more immunogenic cell death modalities, aiming to transform RT from a primarily tumor-debulking modality into a driver of durable anti-tumor immunity.

Year:

2025

Different types of regulated cell death, including ferroptosis, necroptosis, and pyroptosis, can elicit an immune response. In this webinar, our speakers will introduce the concept of inflammatory/immunogenic cell death and discuss its implications for cancer immunity and immunotherapy. The presentations will be followed by a panel discussion and Q A session. The webinar will be hosted by Nature Cancer and Nature Communications editors.

Year:

2025

Year:

2024

Protein kinases act as central molecular switches in the control of cellular functions. Alterations in the regulation and function of protein kinases may provoke diseases including cancer. In this study we investigate the conformational states of such disease-associated kinases using the high sensitivity of the kinase conformation (KinCon) reporter system. We first track BRAF kinase activity conformational changes upon melanoma drug binding. Second, we also use the KinCon reporter technology to examine the impact of regulatory protein interactions on LKB1 kinase tumor suppressor functions. Third, we explore the conformational dynamics of RIP kinases in response to TNF pathway activation and small molecule interactions. Finally, we show that CDK4/6 interactions with regulatory proteins alter conformations which remain unaffected in the presence of clinically applied inhibitors. Apart from its predictive value, the KinCon technology helps to identify cellular factors that impact drug efficacies. The understanding of the structural dynamics of full-length protein kinases when interacting with small molecule inhibitors or regulatory proteins is crucial for designing more effective therapeutic strategies.

Year:

2024

Year:

2023

Collaborators (7)

Zoran Rankovic

Institute of Cancer Research

UNITED KINGDOM
View details

Dmitri V. Krysko

Ghent University

BELGIUM
View details

Eduard Stefan

Group leader

University of Innsbruck

AUSTRIA
View details

Dieter Adam

Christian-Albrechts-Universität zu Kiel

GERMANY
View details

Valentina Kugler

University of Innsbruck

AUSTRIA
View details

Lorenzo Galluzzi

-

UNITED STATES
View details

Teresa Kaserer

University of Innsbruck

AUSTRIA
View details